Organon & Co
OGN7.185USD
+0.095+1.34%
종가 12/26, 16:00（ET）시세는 15분 지연됩니다
1.87B시가총액
3.72P/E TTM
자세한 내용은 Organon & Co 회사
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Organon & Co 정보
종목 코드 OGN
회사 이름Organon & Co
상장일May 14, 2021
CEOMorrissey (Joseph T)
직원 수10000
유형Ordinary Share
회계 연도 종료May 14
주소30 Hudson Street
도시JERSEY CITY
증권 거래소NASDAQ OMX NASDAQ Basic NYSE
국가United States of America
우편 번호07302
전화15514306000
웹사이트https://www.organon.com/
종목 코드 OGN
상장일May 14, 2021
CEOMorrissey (Joseph T)
Organon & Co의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
2.00
--
Ms. Ramona A. Sequeira
Ms. Ramona A. Sequeira
Independent Director
Independent Director
--
--
Mr. Robert A. (Bob) Essner
Mr. Robert A. (Bob) Essner
Lead Independent Director
Lead Independent Director
--
--
Ms. Grace M. Puma Whiteford
Ms. Grace M. Puma Whiteford
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
수익 분석
통화: USD마지막 업데이트: Mon, Oct 6
통화: USD마지막 업데이트: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Women’s Health
462.00M
28.98%
Cardiovascular
283.00M
17.75%
Non-Opioid Pain, Bone and Dermatology
250.00M
15.68%
Respiratory
220.00M
13.80%
Other
206.00M
12.92%
Biosimilars
173.00M
10.85%
지역별USD
이름
수익
비율
Europe and Canada
419.00M
26.29%
United States
414.00M
25.97%
Latin America, Middle East, Russia and Africa
285.00M
17.88%
Asia Pacific and Japan
250.00M
15.68%
China
204.00M
12.80%
Other
22.00M
1.38%
사업별
지역별
사업별USD
이름
수익
비율
Women’s Health
462.00M
28.98%
Cardiovascular
283.00M
17.75%
Non-Opioid Pain, Bone and Dermatology
250.00M
15.68%
Respiratory
220.00M
13.80%
Other
206.00M
12.92%
Biosimilars
173.00M
10.85%
주식 보유 통계
마지막 업데이트: Sun, Nov 16
마지막 업데이트: Sun, Nov 16
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
13.76%
BlackRock Institutional Trust Company, N.A.
10.68%
MFS Investment Management
3.63%
State Street Investment Management (US)
3.59%
LSV Asset Management
3.01%
기타
65.33%
주주
주주
비율
The Vanguard Group, Inc.
13.76%
BlackRock Institutional Trust Company, N.A.
10.68%
MFS Investment Management
3.63%
State Street Investment Management (US)
3.59%
LSV Asset Management
3.01%
기타
65.33%
주주 유형
주주
비율
Investment Advisor
47.62%
Investment Advisor/Hedge Fund
20.77%
Hedge Fund
4.75%
Pension Fund
2.56%
Research Firm
2.06%
Bank and Trust
0.92%
Sovereign Wealth Fund
0.86%
Individual Investor
0.36%
Venture Capital
0.04%
기타
20.06%
기관 주식 보유
마지막 업데이트: Wed, Oct 1
마지막 업데이트: Wed, Oct 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q3
1485
219.88M
84.58%
-37.41M
2025Q2
1527
205.34M
78.98%
-50.49M
2025Q1
1611
213.21M
82.04%
-52.34M
2024Q4
1647
218.39M
84.67%
-40.43M
2024Q3
1625
211.80M
82.26%
-47.57M
2024Q2
1676
208.67M
81.14%
-51.47M
2024Q1
1700
205.29M
80.30%
-45.21M
2023Q4
1767
202.90M
79.38%
-24.07M
2023Q3
1835
205.61M
80.45%
-25.35M
2023Q2
2016
205.94M
80.75%
-21.55M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
32.15M
12.37%
+2.54M
+8.57%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
28.28M
10.88%
-627.34K
-2.17%
Jun 30, 2025
MFS Investment Management
10.11M
3.89%
-469.39K
-4.44%
Jun 30, 2025
State Street Investment Management (US)
9.52M
3.66%
+540.48K
+6.02%
Jun 30, 2025
LSV Asset Management
7.99M
3.07%
+8.69K
+0.11%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.40M
1.69%
-121.50K
-2.69%
Jun 30, 2025
Millennium Management LLC
9.09M
3.5%
+8.11M
+829.74%
Jun 30, 2025
AQR Capital Management, LLC
3.25M
1.25%
+1.88M
+136.10%
Jun 30, 2025
Gotham Asset Management, LLC
2.71M
1.04%
+1.31M
+93.22%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
4.63M
1.78%
+459.24K
+11.02%
Jun 30, 2025
더 보기
관련 ETF
마지막 업데이트: Tue, Dec 2
마지막 업데이트: Tue, Dec 2
이름
비율
State Street SPDR S&P Pharmaceuticals ETF
1.72%
Alger Russell Innovation ETF
1.39%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.22%
First Trust Health Care Alphadex Fund
1.1%
Invesco S&P SmallCap Health Care ETF
1.07%
Brandes US Small-Mid Cap Value ETF
1.05%
iShares U.S. Pharmaceuticals ETF
0.65%
Lattice Hartford Multifactor Small Cap ETF
0.5%
WisdomTree U.S. SmallCap Dividend Fund
0.5%
Royce Quant Small-Cap Quality Value ETF
0.45%
더 보기
State Street SPDR S&P Pharmaceuticals ETF
비율1.72%
Alger Russell Innovation ETF
비율1.39%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
비율1.22%
First Trust Health Care Alphadex Fund
비율1.1%
Invesco S&P SmallCap Health Care ETF
비율1.07%
Brandes US Small-Mid Cap Value ETF
비율1.05%
iShares U.S. Pharmaceuticals ETF
비율0.65%
Lattice Hartford Multifactor Small Cap ETF
비율0.5%
WisdomTree U.S. SmallCap Dividend Fund
비율0.5%
Royce Quant Small-Cap Quality Value ETF
비율0.45%
주식 배당금
지난 5년 동안 총
1.03B
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
Nov 10, 2025
OGN.NB Final Cash Dividend of gross USD 0.02 paid on Dec 11, 2025 going ex on Nov 20, 2025
Nov 20, 2025
Dec 11, 2025
Nov 20, 2025
Aug 05, 2025
OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Sep 11, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Sep 11, 2025
Aug 15, 2025
May 01, 2025
OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Jun 12, 2025 going ex on May 12, 2025
May 12, 2025
Jun 12, 2025
May 12, 2025
Feb 13, 2025
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 13, 2025 going ex on Feb 24, 2025
Feb 24, 2025
Mar 13, 2025
Feb 24, 2025
Oct 31, 2024
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 12, 2024 going ex on Nov 12, 2024
Nov 12, 2024
Dec 12, 2024
Nov 12, 2024
Aug 06, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 12, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 12, 2024
Aug 16, 2024
May 02, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 13, 2024 going ex on May 10, 2024
May 13, 2024
Jun 13, 2024
May 10, 2024
Feb 15, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 14, 2024 going ex on Feb 23, 2024
Feb 26, 2024
Mar 14, 2024
Feb 23, 2024
Nov 02, 2023
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 14, 2023 going ex on Nov 10, 2023
Nov 13, 2023
Dec 14, 2023
Nov 10, 2023
Aug 08, 2023
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 14, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 14, 2023
Aug 17, 2023
더 보기
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
자주 묻는 질문
Organon & Co의 상위 5대 주주는 누구인가요?
Organon & Co의 상위 5대 주주는 다음과 같습니다:
The Vanguard Group, Inc.는 32.15M주의 주식을 보유하고 있으며, 전체 주식의 12.37%를 차지합니다.
BlackRock Institutional Trust Company, N.A.는 28.28M주의 주식을 보유하고 있으며, 전체 주식의 10.88%를 차지합니다.
MFS Investment Management는 10.11M주의 주식을 보유하고 있으며, 전체 주식의 3.89%를 차지합니다.
State Street Investment Management (US)는 9.52M주의 주식을 보유하고 있으며, 전체 주식의 3.66%를 차지합니다.
LSV Asset Management는 7.99M주의 주식을 보유하고 있으며, 전체 주식의 3.07%를 차지합니다.
The Vanguard Group, Inc.는 32.15M주의 주식을 보유하고 있으며, 전체 주식의 12.37%를 차지합니다.
BlackRock Institutional Trust Company, N.A.는 28.28M주의 주식을 보유하고 있으며, 전체 주식의 10.88%를 차지합니다.
MFS Investment Management는 10.11M주의 주식을 보유하고 있으며, 전체 주식의 3.89%를 차지합니다.
State Street Investment Management (US)는 9.52M주의 주식을 보유하고 있으며, 전체 주식의 3.66%를 차지합니다.
LSV Asset Management는 7.99M주의 주식을 보유하고 있으며, 전체 주식의 3.07%를 차지합니다.
Organon & Co의 상위 3대 주주 유형은 무엇인가요?
Organon & Co의 주요 주주 유형 상위 3가지는
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
MFS Investment Management입니다.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
MFS Investment Management입니다.
Organon & Co(OGN)의 주식을 보유한 기관은 몇 개입니까?
2025Q3 기준으로, Organon & Co의 주식을 보유한 기관은 총 1485곳이며, 이들이 보유한 주식의 총 가치는 약 219.88M로 전체 발행 주식의 84.58%를 차지합니다. 이는 2025Q2 대비 5.59% 증가한 수치입니다.
Organon & Co의 최대 수익원은 무엇인가요?
FY2025Q2 기준, Organon & Co의 Women’s Health 부문이 가장 높은 매출을 기록했으며, 금액은 462.00M로 전체 매출의 28.98%를 차지했습니다.
